Department of Cardiology, The Second Affiliated Hospital of Kunming Medical University, No. 374, Dianmian Road, Kunming, Yunnan, 650101, China.
Sci Rep. 2019 Jan 24;9(1):453. doi: 10.1038/s41598-018-37520-8.
No previous study reports the effect of age on cardiac performance, motor function and quality of life (QoL) in Chinese chronic heart failure (CHF) patients. This single-center, prospective study enrolled CHF patients with resting heart rate (RHR) > 80 bpm, who were treated with metoprolol and were followed up at 1, 3, 6, and 12 months. Changes in cardiac, motor, and QoL parameters between patients aged ≥60 years and those aged <60 years were compared at all time points. P < 0.05 was considered significant. A total of 154 patients were enrolled (median age: 66.39 years; 116 aged ≥60 years, 38 aged <60 years; 95% New York Heart Association class III-IV). RHR decreased significantly in both patient groups (P < 0.0001 for both groups). Patients aged ≥60 years had a significant improvement in both ejection fraction (EF) at 6 and 12 months and in cardiac index (CI) at 3, 6, and 12 months. However, no major difference was observed in motor function in both groups. Significantly higher SF-8 scores showed greater improvement in QoL in the <60 age group at 12 months (P = 0.0008). Metoprolol demonstrated improvement in cardiac performance, motor function, QoL, and anxiety with increase in depression and burnout in both genders; however, the findings were independent of age.
先前的研究尚未报告年龄对中国慢性心力衰竭(CHF)患者心脏功能、运动功能和生活质量(QoL)的影响。这项单中心、前瞻性研究纳入了静息心率(RHR)>80 次/分、接受美托洛尔治疗且在 1、3、6 和 12 个月时接受随访的 CHF 患者。比较了所有时间点年龄≥60 岁和<60 岁患者之间心脏、运动和 QoL 参数的变化。P<0.05 被认为具有统计学意义。共纳入 154 例患者(中位年龄:66.39 岁;116 例年龄≥60 岁,38 例年龄<60 岁;95%纽约心脏协会心功能分级 III-IV 级)。两组患者的 RHR 均显著降低(两组均 P<0.0001)。年龄≥60 岁的患者在 6 个月和 12 个月时射血分数(EF)以及在 3、6 和 12 个月时心指数(CI)均显著改善。然而,两组的运动功能均无明显差异。<60 岁年龄组的 SF-8 评分显著升高,表明 12 个月时 QoL 改善更明显(P=0.0008)。美托洛尔在两性中均显示出改善心脏功能、运动功能、QoL 和焦虑,同时增加抑郁和倦怠;然而,这些发现与年龄无关。